Literature DB >> 1873305

Measurement of the class III antidysrhythmic drug, UK-68,798, in plasma by radioimmunoassay.

D K Walker1, G W Aherne, J E Arrowsmith, P E Cross, B Kaye, D A Smith, D A Stopher, W Wild.   

Abstract

A sensitive radioimmunoassay (RIA) for the specific determination of 1-(4-methanesulphonamidophenoxy)-2-[N-(4-methanesulphonamido -phenethyl)-N- methylamino]ethane (UK-68,798), a novel class III antidysrhythmic agent, in human plasma is described. Specific antisera were raised in sheep using desmesyl-UK-68,798-succinate-ovalbumin conjugate as the antigenic hapten carrier protein. The antisera produced exhibited high specificity for UK-68,798 compared with known metabolites from animals, other antidysrhythmic agents and co-administered drugs. Good correlation was found in a comparison of the RIA method with a high-performance liquid chromatography (HPLC) method (r = 0.997) and a 10-fold lower limit of determination was observed for the RIA method compared with the HPLC method (0.05 and 0.5 ng ml-1, respectively). The RIA method was applied to the analysis of UK-68,798 in plasma obtained from human volunteers receiving the compound.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1873305     DOI: 10.1016/0731-7085(91)80137-x

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  5 in total

1.  The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data.

Authors:  Karin Tunblad; Lars Lindbom; Lynn McFadyen; E Niclas Jonsson; Scott Marshall; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-11-15       Impact factor: 2.745

2.  A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers.

Authors:  J D Gemmill; C A Howie; P A Meredith; A W Kelman; H S Rasmussen; W S Hillis; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

3.  The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing.

Authors:  M J Allen; D J Nichols; S D Oliver
Journal:  Br J Clin Pharmacol       Date:  2000-09       Impact factor: 4.335

4.  Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide.

Authors:  S Abel; D J Nichols; C J Brearley; M D Eve
Journal:  Br J Clin Pharmacol       Date:  2000-01       Impact factor: 4.335

5.  Effects of intravenous dofetilide on induction of atrioventricular re-entrant tachycardia.

Authors:  S M Cobbe; R W Campbell; A J Camm; A W Nathan; E Rowland; P E Bloch-Thomsen; M Møller; L Jordaens
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.